Telomerase-targeting compounds Imetelstat and 6-thio-dG act synergistically with chemotherapy in high-risk neuroblastoma models.

Janina FischerFelix OtteAndrea RoderwieserCarolina RosswogYvonne KahlertLisa WerrAnna-Maria HellmannMaya BerdingBill ChiuChristoph BartenhagenMatthias Fischer

Published in: Cellular oncology (Dordrecht) (2022)

Our study indicates that telomerase is an actionable target in telomerase-positive neuroblastoma, and demonstrates that combination therapies including telomerase-interacting compounds may improve the efficacy of established cytotoxic drugs. Targeting telomerase may thus represent a therapeutic option in high-risk neuroblastoma patients.

Keyphrases

end stage renal disease
ejection fraction
chronic kidney disease
peritoneal dialysis
prognostic factors
radiation therapy
patient reported
rectal cancer